Back to Search Start Over

Community Collaboration to Advance Racial/Ethnic Equity in Colorectal Cancer Screening: Protocol for a Multilevel Intervention to Improve Screening and Follow-up in Community Health Centers.

Authors :
May FP
Brodney S
Tuan JJ
Syngal S
Chan AT
Glenn B
Johnson G
Chang Y
Drew DA
Moy B
Rodriguez NJ
Warner ET
Anyane-Yeboa A
Ukaegbu C
Davis AQ
Schoolcraft K
Regan S
Yoguez N
Kuney S
Le Beaux K
Jeffries C
Lee ET
Bhat R
Haas JS
Source :
Contemporary clinical trials [Contemp Clin Trials] 2024 Oct; Vol. 145, pp. 107639. Date of Electronic Publication: 2024 Jul 26.
Publication Year :
2024

Abstract

Introduction: Colorectal cancer (CRC) screening utilization is low among low-income, uninsured, and minority populations that receive care in community health centers (CHCs). There is a need for evidence-based interventions to increase screening and follow-up care in these settings.<br />Methods: A multilevel, multi-component pragmatic cluster randomized controlled trial is being conducted at 8 CHCs in two metropolitan areas (Boston and Los Angeles), with two arms: (1) Mailed FIT outreach with text reminders, and (2) Mailed FIT-DNA with patient support. We also include an additional CHC in Rapid City (South Dakota) that follows a parallel protocol for FIT-DNA but is not randomized due to lack of a comparison group. Eligible individuals in participating clinics are primary care patients ages 45-75, at average-risk for CRC, and overdue for CRC screening. Participants with abnormal screening results are offered navigation for follow-up colonoscopy and CRC risk assessment.<br />Results: The primary outcome is the completion rate of CRC screening at 90 days. Secondary outcomes include the screening completion rate at 180 days and the rate of colonoscopy completion within 6 months among participants with an abnormal result. Additional goals are to enhance our understanding of facilitators and barriers to CRC risk assessment in CHC settings.<br />Conclusions: This study assesses the effectiveness of two multilevel interventions to increase screening participation and follow-up after abnormal screening in under-resourced clinical settings, informing future efforts to address CRC disparities.<br />Trial Registration: NCT05714644.<br />Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Folasade P. May: Exact Sciences: Advisory Board Sapna Syngal: inventor of the PREMM model (the intellectual property of which is owned by Dana-Farber Cancer Institute); research funding by Exact Sciences, Biological Dynamics, Inc.; consultant for Natera, Inc.<br /> (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1559-2030
Volume :
145
Database :
MEDLINE
Journal :
Contemporary clinical trials
Publication Type :
Academic Journal
Accession number :
39068985
Full Text :
https://doi.org/10.1016/j.cct.2024.107639